Recent Updates
Recently added Catalysts
LAB Positive Sentiment Score: 75/100

Standard BioTools to Present at the Jefferies Healthcare Conference

Key Takeaway: Standard BioTools Inc. announced that its CEO, Michael Egholm, will present at the Jefferies Healthcare Conference on June 8, 2023. The presentation will focus on the company's innovations and contributions to human health. As a recognized provider of next-generation technologies, Standard BioTools aims to enhance the efficiency of biomedical research. The event is part of their ongoing efforts to showcase their proprietary technologies in areas such as oncology and immunology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Standard BioTools is presenting at a high-profile conference, which indicates industry recognition.
  • The CEO's involvement suggests confidence in the company's direction.
  • The company's mission to accelerate breakthroughs in human health aligns with current industry needs.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:00 a.m. ET.
The presentation will be webcast live and available on the Investor Relations page of the company’s website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools™ products are provided for Research Use Only. Not for use in diagnostic procedures.
Scott R. Greenstone, CFA

Frequently Asked Questions

When is Michael Egholm's presentation at the Jefferies Healthcare Conference?

Michael Egholm's presentation is on June 8, 2023, at 9:00 a.m. ET.

Where can I watch Standard BioTools' live presentation?

You can watch the live presentation on the company's Investor Relations page.

What is the focus of Standard BioTools Inc.?

Standard BioTools Inc. focuses on accelerating breakthroughs in human health.

What technologies does Standard BioTools use?

The company utilizes mass cytometry and microfluidics technologies.

Who collaborates with Standard BioTools?

Standard BioTools works with academic, government, and clinical laboratories globally.

Last updated: May 25, 2023